Antonio Mulero‐Sánchez

864 total citations
6 papers, 255 citations indexed

About

Antonio Mulero‐Sánchez is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Antonio Mulero‐Sánchez has authored 6 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 2 papers in Oncology and 1 paper in Infectious Diseases. Recurrent topics in Antonio Mulero‐Sánchez's work include Protein Tyrosine Phosphatases (2 papers), CRISPR and Genetic Engineering (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Antonio Mulero‐Sánchez is often cited by papers focused on Protein Tyrosine Phosphatases (2 papers), CRISPR and Genetic Engineering (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Antonio Mulero‐Sánchez collaborates with scholars based in Netherlands, Spain and Switzerland. Antonio Mulero‐Sánchez's co-authors include René Bernards, Cor Lieftink, Astrid Bosma, Sara Mainardi, Giovanni Germano, Alberto Bardelli, Samuel Gonçalves-Ribeiro, Jeffrey Steinberg, Alberto Villanueva and Ernest Nadal and has published in prestigious journals such as Nature Medicine, Annals of Oncology and Molecular Oncology.

In The Last Decade

Antonio Mulero‐Sánchez

6 papers receiving 252 citations

Peers

Antonio Mulero‐Sánchez

MB

ONCOL

IMMUN

PRM

CR

Brian Diskin United States

D. Lucas Kerr United States

Viacheslav V. Senichkin Sweden

Katia Bouchekioua‐Bouzaghou France

Rebecca A. Bilardi Australia

Valeria Sanabria Guillen United States

Javier Pérez‐Peña Spain

Sandrine Agoussi France

Ute Jucknischke Switzerland

Marcos J. Ruiz United States

Brian Diskin United States

Antonio Mulero‐Sánchez

177 ×0.8

MB

83 ×0.9

ONCOL

64 ×0.9

IMMUN

27 ×0.7

PRM

33 ×1.4

CR

Citations per year, relative to Antonio Mulero‐Sánchez Antonio Mulero‐Sánchez (= 1×) peers Brian Diskin

Countries citing papers authored by Antonio Mulero‐Sánchez

Since Specialization

Citations

This map shows the geographic impact of Antonio Mulero‐Sánchez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Mulero‐Sánchez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Mulero‐Sánchez more than expected).

Fields of papers citing papers by Antonio Mulero‐Sánchez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Mulero‐Sánchez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Mulero‐Sánchez. The network helps show where Antonio Mulero‐Sánchez may publish in the future.

Co-authorship network of co-authors of Antonio Mulero‐Sánchez

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Mulero‐Sánchez. A scholar is included among the top collaborators of Antonio Mulero‐Sánchez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Mulero‐Sánchez. Antonio Mulero‐Sánchez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Cottu, P., Hai Hu, Joana Ribeiro, et al.. (2025). 296O Risk of recurrence (ROR) after neoadjuvant ribociclib plus ET in clinically high-risk ER+/HER2− BC: Preliminary analysis of the SOLTI-RIBOLARIS trial. Annals of Oncology. 36. S306–S307. 1 indexed citations

2.

Mulero‐Sánchez, Antonio, Astrid Bosma, René Bernards, et al.. (2023). 1630P Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers. Annals of Oncology. 34. S902–S903. 2 indexed citations

3.

Mulero‐Sánchez, Antonio, Christel Ramirez, Aimée du Chatinier, et al.. (2023). Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma. Molecular Oncology. 17(6). 964–980. 11 indexed citations

4.

Pogacar, Ziva, Fleur Jochems, Antonio Mulero‐Sánchez, et al.. (2022). Genetic and compound screens uncover factors modulating cancer cell response to indisulam. Life Science Alliance. 5(9). e202101348–e202101348. 8 indexed citations

5.

Mulero‐Sánchez, Antonio, Ziva Pogacar, & Loredana Vecchione. (2019). Importance of genetic screens in precision oncology. ESMO Open. 4(3). e000505–e000505. 7 indexed citations

6.

Mainardi, Sara, Antonio Mulero‐Sánchez, Anirudh Prahallad, et al.. (2018). SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nature Medicine. 24(7). 961–967. 226 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact